(CAD)
Q1 2026
% Change vs.Q1 2025
TTMMar 31, 2026
% Change vs.TTMMar 31, 2025
Pharmaceutical Sales
10,803,107
+1%
40,987,981
+11%
Oral Health Sales
2,984,973
n/a
2,984,973
n/a
Insecticide Sales
120,102
-58%
2,008,251
+59%
Total Company Sales
13,908,182
+27%
45,981,205
+20%
EBITDA1
3,639,086
+14%
12,560,195
+21%
Net Income After Taxes (NIAT)
2,344,819
+1%
9,287,118
+16%
Fully Diluted EPS
0.20
-
0.78
+16%
Completed acquisition of Oral Science Inc., a Canadian owner and distributor of specialized dental hygiene and oral health products, as announced on March 2, 2026
Additional sales and EBITDA of $2,984,973 and $482,089 respectively, generated by Oral Health business during the month of March 2026 following acquisition of Oral Science Inc.
Q1 2026 EBITDA, adjusted for one-time Oral Science acquisition transaction costs incurred during the quarter, was $3,912,116, +22% vs. year ago
Q1 2026 NIAT, adjusted for one-time Oral Science acquisition transaction costs, was $2,545,496, +10% vs. year ago
Q1 2026 Fully Diluted EPS, adjusted for one-time Oral Science acquisition transaction costs, was $0.22, +$0.02 vs. year ago
TTM March 31, 2026 Fully Diluted EPS, adjusted for one-time Oral Science acquisition transaction costs, was $0.83, +$0.16 vs. year ago
Return on Average Equity for the trailing twelve months (‘TTM') ended March 31, 2026 was 22%, consistent with TTM March 31, 2025
During Q1 2026, repurchased for cancellation a total of 100,000 common shares under a Normal Course Issuer Bid (NCIB)
Paid quarterly cash dividends of $0.055 per common share on March 13, 2026, a 10% increase from the previous quarterly dividend
"We are pleased to have closed the acquisition of Oral Science during the first quarter with an immediate contribution of revenue and profit from the Oral Health business recognized in the month of March," commented Mr. René Goehrum, President and CEO of BioSyent. "In our existing Pharmaceutical business, Canadian sales grew by 9%, driven by our FeraMAX® and Tibella® brands. Internationally, we continued to ship FeraMAX® to customers in the Middle East in spite of geopolitical turmoil in the region. We also continued to make ongoing shipments of Tibelia® to international customers, though sales declined versus Q1 2025 during which a significant backlog of customer orders were delivered following our acquisition of this business late in 2024. With ongoing conflict in the Middle East and growing trade protectionism, there is much uncertainty in the business environment. Nonetheless, we are well-positioned to weather this current uncertainty and to maximize opportunities for continued growth with the addition of our Oral Health business and a more diversified product portfolio, customer base and market. I look forward to reporting on our progress during 2026 as we remain focused on our strategic priorities of profitable growth, portfolio diversification and long-term value creation for our shareholders."
The CEO's presentation on the Q1 2026 Results is available at the following link: www.biosyent.com/investors/
The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2026 and 2025 will be posted on www.sedarplus.ca on May 14, 2026.
The Company further announces that its Board of Directors has approved a grant of 339 Restricted Share Units ("RSUs") to a certain employee of the Company pursuant to the Company's RSU Plan. These RSUs will fully vest within three years on the third anniversary of the applicable grant date.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.
As of the date of this press release, the Company has 11,438,318 common shares outstanding.
BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Comprehensive Income
In Canadian Dollars
